(Q57265384)

English

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

scholarly article by Matthieu Allez et al published October 2010 in Journal of Crohn's and Colitis

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects (English)

0 references

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

inflammatory bowel diseases

1 reference

based on heuristic

inferred from title

Konstantinos Karmiris

object named as

Konstantinos Karmiris

2

0 references

Gert Van Assche

4

object named as

Gert Van Assche

0 references

Shomron Ben-Horin

5

object named as

Shomron Ben-Horin

0 references

9

object named as

Rami Eliakim

0 references

13

object named as

Silvio Danese

0 references

Séverine Vermeire

14

object named as

Severine Vermeire

0 references

3

object named as

Edouard Louis

0 references

author name string

Matthieu Allez

1

0 references

Amir Klein

6

0 references

Janneke Van der Woude

7

0 references

Filip Baert

8

0 references

Konstantinos Katsanos

10

0 references

Jørn Brynskov

11

0 references

Flavio Steinwurz

12

0 references

Jean-Luc Teillaud

15

0 references

Marc Lémann

16

0 references

Yehuda Chowers

17

0 references

publication date

October 2010

0 references

Journal of Crohn's and Colitis

0 references

4

0 references

4

0 references

355-366

0 references

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Immunogenicity of engineered antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Elimination mechanisms of therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

The transmission of immunity from mother to young and the catabolism of immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

FcRn: the MHC class I-related receptor that is more than an IgG transporter

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

An engineered human IgG1 antibody with longer serum half-life.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.04.004

21 January 2018

Identifiers

10.1016/J.CROHNS.2010.04.004

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57265384&oldid=1569419455"